查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433586

美國癌症顯影劑市場規模、佔有率和趨勢分析報告：按類型、方式、應用和細分市場預測，2024-2030 年

U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report By Type, By Modality, By Application, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 94 Pages | 商品交期: 2-10個工作天內

價格

美國癌症顯影劑市場的成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，美國癌症顯影劑市場預計將達到15.3億美元，2024年至2030年的複合年成長率為11.7%。

主要市場參與者之間不斷加強的合作和夥伴關係、政府和私營部門研發投資的增加以及人工智慧在診斷成像中的整合正在增強造影顯影劑的能力。因此，這些因素正在推動美國癌症顯影劑市場的成長。

新產品的推出增加了製造商之間的競爭，促進創新，降低價格，並最終增加患者和醫療保健提供者的選擇。整體市場擴張的潛力取決於新型顯影劑的生產，這些造影劑可提供更高的安全性、增強的目標特異性和獨特的成像特性。這為診斷和治療開闢了新途徑。例如，2023 年 4 月，GE Healthcare 透過向其 MRI 藥物基本客群引入兩種優質大環化合物 Clariscan（钆特酸）和 Pixoscan（钆布醇）擴大了造影顯影劑範圍。該行業的主要企業正在努力擴大產品系列，向市場推出新產品，並加強研發，從而推動市場成長。

此外，醫療保健預算的增加通常會鼓勵公共衛生舉措，促進癌症的早期發現和改善先進診斷工具的取得。這些努力提高了人們對造影影像重要性的認知，並增加了對相應顯影劑的需求。增加的醫療保健預算吸引了新進入者並激勵現有相關人員參與市場競爭。這種動態刺激了創新，促進了價格競爭，並最終為醫療保健專業人員和患者提供了更多選擇。這些舉措正在為市場擴張創造有利可圖的機會。

美國癌症顯影劑市場報告亮點

  • 由於醫學影像診斷的增加，碘顯影劑在該類型細分市場中佔據主導地位，到 2023 年，其佔有率將達到 39.5%。
  • 預計放射性藥物領域在預測期內將以最快的複合年成長率成長。
  • 核子醫學影像領域在預測期內佔據最大市場佔有率，到 2023 年將達到 38.2%，因為它能夠提供體內結構和功能的詳細而準確的圖像，從而為醫療保健專業人員提供準確的診斷。期間成長最快
  • 久坐的生活方式、吸菸率的增加和空氣污染的加劇導致美國癌症盛行率不斷上升。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國癌症顯影劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國癌症顯影劑市場：法律規範、標準和合規性
  • 美國癌症顯影劑市場：報銷方案
  • 美國癌症顯影劑市場：分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國癌症顯影劑市場：類型估計和趨勢分析

  • 類型市場佔有率，2023 年和 2030 年
  • 細分儀表板
  • 美國癌症顯影劑市場：按類型分類的前景

第5章美國癌症顯影劑市場：模態估計與趨勢分析

  • 2023年及2030年醫療器材市場佔有率
  • 細分儀表板
  • 美國癌症顯影劑市場前景：依方式分類

第6章美國癌症顯影劑市場：應用預估及趨勢分析

  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 美國癌症顯影劑市場前景：依應用分類

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Bayer AG
    • Lantheus
    • Bracco
    • Guerbet
    • Trivitron Healthcare
    • Cardinal Health
    • Telix Pharmaceuticals Limited
    • GE HealthCare
    • IMAX Diagnostic Imaging
    • Nano Therapeutics Pvt. Ltd.
Product Code: GVR-4-68040-184-8

U.S. Cancer Contrast Media Market Growth & Trends:

The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing collaboration and partnerships among key market players, coupled with growing government and private sector R&D investments, alongside the integration of AI in diagnostic imaging enhance the capabilities of contrast media. Thus, these factors collectively propel the growth of U.S. cancer contrast media market.

Introducing new products can ignite positive competition among manufacturers, fostering innovation, lowering prices, and ultimately enhancing choices for both patients and healthcare providers. The potential for expanding the overall market depends upon the manufacturing of novel contrast agents that offer heightened safety, enhanced target specificity, or distinctive imaging properties. This opens up new pathways for both diagnosis and treatment. For instance, in April 2023 , GE Healthcare has broadened its range of contrast media by introducing two premier macrocyclic molecules, namely Clariscan (gadoteric acid) and Pixxoscan (gadobutrol), to its customer base for MRI agents. The industry key players are involved in enhancing R&D by introducing novel products to the market by expanding their product portfolio, which drives market growth.

Moreover, increased funding in healthcare budgets often facilitates public health initiatives promoting early cancer detection and enhanced accessibility to advanced diagnostic tools. These initiatives enhance awareness of the importance of contrast-enhanced imaging, consequently fueling demand for corresponding contrast media. The growth in healthcare budgets attracts new players and motivates existing stakeholders to compete in the market. This dynamic stimulates innovation, fosters price competitiveness, and ultimately leads to a broader range of options for both healthcare providers and patients. Such initiatives create a lucrative opportunity for market expansion.

U.S. Cancer Contrast Media Market Report Highlights:

  • Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.
  • The radioactive agents segment is expected to grow at the fastest CAGR over the forecast period.
  • The nuclear imaging segment held the largest market share of 38.2% in 2023 and is anticipated to witness fastest growth over the forecast period owing to its ability to provide detailed and accurate images of internal structures and functions within the body which allows healthcare professionals for precise diagnosis.
  • Sedentary lifestyle, increasing incidences of smoking and rising air pollution are contributing to the growing prevalence of cancer cases in U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Modality
    • 1.2.3. Application
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Modality outlook
    • 2.2.3. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Cancer Contrast Media Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing number of clinical studies
      • 3.2.1.2. Rising cancer cases
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Side effects and adverse reactions related to contrast agents
      • 3.2.2.2. Presence of alternative imaging options
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Increasing demand for medical imaging
    • 3.2.4. Market challenges analysis
      • 3.2.4.1. Shortage of contrast media due to supply chain disruptions
  • 3.3. U.S. Cancer Contrast Media Market: Regulatory Framework and Standards & Compliances
  • 3.4. U.S. Cancer Contrast Media Market: Reimbursement Scenario
  • 3.5. U.S. Cancer Contrast Media Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. U.S. Cancer Contrast Media Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Cancer Contrast Media Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Gadolinium-based Contrast Media
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Iodinated Contrast Media
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Radioactive Agents
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Cancer Contrast Media Market: Modality Estimates & Trend Analysis

  • 5.1. Modality Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Cancer Contrast Media Market by Modality Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Nuclear Imaging
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. CT scans
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Mammography
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. MRI scans
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Ultrasound
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Cancer Contrast Media Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Cancer Contrast Media Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Breast Cancer
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Bladder Cancer
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Colorectal Cancer
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Lung Cancer
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Prostate Cancer
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Bayer AG
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Lantheus
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Bracco
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Guerbet
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Trivitron Healthcare
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Cardinal Health
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Telix Pharmaceuticals Limited
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. GE HealthCare
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. IMAX Diagnostic Imaging
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Nano Therapeutics Pvt. Ltd.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. cancer contrast media market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. cancer contrast media market, by modality, 2018 - 2030 (USD Million)
  • Table 4 U.S. cancer contrast media market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. cancer contrast media market: market outlook
  • Fig. 10 U.S. cancer contrast media competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. cancer contrast media market driver impact
  • Fig. 16 U.S. cancer contrast media market restraint impact
  • Fig. 17 U.S. cancer contrast media market strategic initiatives analysis
  • Fig. 18 U.S. cancer contrast media market: Type movement analysis
  • Fig. 19 U.S. cancer contrast media market: Type outlook and key takeaways
  • Fig. 20 Gadolinium-based contrast media market estimates and forecast, 2018 - 2030
  • Fig. 21 Iodinated contrast media estimates and forecast, 2018 - 2030
  • Fig. 22 Radioactive agents market estimates and forecast, 2018 - 2030
  • Fig. 23 Others estimates and forecast, 2018 - 2030
  • Fig. 24 U.S. cancer contrast media Market: Modality movement Analysis
  • Fig. 25 U.S. cancer contrast media market: Modality outlook and key takeaways
  • Fig. 26 Nuclear imaging market estimates and forecasts, 2018 - 2030
  • Fig. 27 CT scans market estimates and forecasts, 2018 - 2030
  • Fig. 28 Mammography market estimates and forecasts, 2018 - 2030
  • Fig. 29 MRI scans market estimates and forecasts, 2018 - 2030
  • Fig. 30 Ultrasound market estimates and forecasts, 2018 - 2030
  • Fig. 31 U.S. cancer contrast media market: Application movement analysis
  • Fig. 32 U.S. cancer contrast media market: Application outlook and key takeaways
  • Fig. 33 Colorectal cancer market estimates and forecasts, 2018 - 2030
  • Fig. 34 Bladder cancer market estimates and forecasts, 2018 - 2030
  • Fig. 35 Breast cancer market estimates and forecasts, 2018 - 2030
  • Fig. 36 Lung cancer market estimates and forecasts, 2018 - 2030
  • Fig. 37 Prostate cancer market estimates and forecasts, 2018 - 2030
  • Fig. 38 Other market estimates and forecasts, 2018 - 2030
  • Fig. 39 Market share of key market players - U.S. cancer contrast media market
  • Fig. 40 Key company categorization
  • Fig. 41 Company market positioning
  • Fig. 42 Key company market share analysis, 2023
  • Fig. 43 Strategic framework